Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sclerosing cholangitis.

George R MacFaul1, Roger W Chapman

  • 1Department of Gastroenterology, John Radcliffe Hospital, Oxford, UK.

Current Opinion in Gastroenterology
|April 9, 2005
PubMed
Summary
This summary is machine-generated.

Primary sclerosing cholangitis (PSC) is an immune-mediated liver disease with increasing prevalence. Research highlights genetic factors, diagnostic accuracy of MRCP, and promising outcomes for liver transplantation in end-stage PSC.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD.

Journal of pediatric gastroenterology and nutrition·2024
Same author

Dye-based chromoendoscopy detects more neoplasia than white light endoscopy in patients with primary sclerosing cholangitis and IBD.

Endoscopy international open·2024
Same author

Primary sclerosing cholangitis-A long night's journey into day.

Clinical liver disease·2022
Same author

Prevalence and long-term outcome of sub-clinical primary sclerosing cholangitis in patients with ulcerative colitis.

Liver international : official journal of the International Association for the Study of the Liver·2020
Same author

Review of primary sclerosing cholangitis with increased IgG4 levels.

World journal of gastroenterology·2020
Same author

Experience from the first UK inter-regional specialist multidisciplinary meeting in the diagnosis and management of IgG4-related disease.

Clinical medicine (London, England)·2020
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
See all related articles

Area of Science:

  • Hepatology
  • Immunology
  • Gastroenterology

Background:

  • Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease affecting the biliary tree.
  • The exact cause of PSC is unknown, but it is considered immune-mediated.
  • Recent studies indicate a higher prevalence and disease burden than previously recognized.

Purpose of the Study:

  • To review current research on the etiopathogenesis, epidemiology, diagnosis, and treatment of PSC.
  • To discuss cholangiocarcinoma in PSC patients.
  • To evaluate liver transplantation outcomes for PSC.

Main Methods:

  • Review of recent scientific literature on primary sclerosing cholangitis.
  • Analysis of genetic heterogeneity and polymorphisms.

Related Experiment Videos

  • Comparison of diagnostic imaging modalities (MRCP vs. ERCP).

    • Main Results:

    • Genetic heterogeneity in PSC is confirmed, with new protective gene polymorphisms identified.
    • Magnetic resonance cholangiopancreatography (MRCP) is a cost-effective and accurate diagnostic tool, superior to ERCP.
    • Ursodeoxycholic acid shows potential as a chemopreventive agent for cancers.
    • Liver transplantation is the sole curative option for end-stage PSC, with good survival rates, though retransplantation rates are higher.

    Conclusions:

    • Further understanding of PSC pathogenesis is needed.
    • MRCP is recommended for PSC diagnosis.
    • Liver transplantation offers favorable outcomes for end-stage PSC, including those with hepatobiliary malignancy.
    • Ursodeoxycholic acid may play a role in cancer prevention.